Cefixime

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefixime and Ofloxacin is a fixed-dose combination antibiotic combining a 3rd-generation cephalosporin and a broad-spectrum fluoroquinolone. Cefixime inhibits cell wall synthesis, while ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, halting DNA replication. This dual mechanism provides synergistic bactericidal coverage against resistant pathogens. Indicated for enteric fever (typhoid fever), severe respiratory tract infections, complicated urinary tract infections, and mixed bacterial pelvic infections.

Cefixime and Potassium Clavulanate combines an oral third-generation cephalosporin with a potent beta-lactamase inhibitor. Clavulanic acid inactivates class A and other beta-lactamases, restoring and broadening cefixime's bactericidal potency against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Klebsiella pneumoniae. Indicated for refractory otitis media, acute bacterial sinusitis, community-acquired pneumonia, and complicated urinary tract infections.

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefixime is an oral third-generation cephalosporin bactericidal antibiotic. It acts by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Demonstrates high stability against beta-lactamase enzymes. Indicated for uncomplicated urinary tract infections, otitis media, pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, uncomplicated gonorrhoea, and enteric (typhoid) fever.

Cefixime and Potassium Clavulanate combines an oral third-generation cephalosporin with a potent beta-lactamase inhibitor. Clavulanic acid inactivates class A and other beta-lactamases, restoring and broadening cefixime's bactericidal potency against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Klebsiella pneumoniae. Indicated for refractory otitis media, acute bacterial sinusitis, community-acquired pneumonia, and complicated urinary tract infections.

Cefixime and Potassium Clavulanate combines an oral third-generation cephalosporin with a potent beta-lactamase inhibitor. Clavulanic acid inactivates class A and other beta-lactamases, restoring and broadening cefixime's bactericidal potency against beta-lactamase-producing Haemophilus influenzae, Moraxella catarrhalis, E. coli, and Klebsiella pneumoniae. Indicated for refractory otitis media, acute bacterial sinusitis, community-acquired pneumonia, and complicated urinary tract infections.

Cefixime and Moxifloxacin combination pairs a 3rd-generation oral cephalosporin with a respiratory fluoroquinolone. Provides enhanced dual coverage against typical and atypical respiratory pathogens, resistant Gram-negative bacilli, and anaerobes. Indicated for severe or refractory community-acquired pneumonia, acute exacerbations of chronic bronchitis, and complicated polymicrobial infections.

Cefixime, Cloxacillin (Extended Release), and Lactic Acid Bacillus is a broad-spectrum anti-infective formulation. Cefixime delivers extended Gram-negative coverage, cloxacillin resists staphylococcal penicillinases to eradicate resistant Gram-positive staphylococci, and probiotic Lactic Acid Bacillus restores intestinal flora. Indicated for mixed respiratory infections, cellulitis, surgical wound infections, and ENT infections.